Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Armstrong

Showing results (911-920 of 1,035) with videos related to

Pageof 104
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian CancerStephanie L Wethington, Payal D Shah, Lainie Martin, et al.
International Journal of Cancer|April 23, 2016
Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanomaNicholas J Taylor, Nancy E Thomas, Hoda Anton-Culver, et al.
Gynecologic Oncology|February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology studyJessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based studyMarianne Berwick, Irene Orlow, Amanda J Hummer, et al.
Breast Cancer Research and Treatment|December 19, 2018
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapiesBerry Button, Sarah Croessmann, David Chu, et al.
Cancer Causes & Control : CCC|January 9, 2007
Ambient UV, personal sun exposure and risk of multiple primary melanomasAnne Kricker, Bruce K Armstrong, Chris Goumas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancerA M Hong, A Martin, B K Armstrong, et al.
The British Journal of Dermatology|September 15, 2019
A risk prediction model for the development of subsequent primary melanoma in a population-based cohortA E Cust, C Badcock, J Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline UpdateStéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, et al.
BMC Cancer|October 19, 2013
MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family studyAnne E Cust, Chris Goumas, Kylie Vuong, et al.
Pageof 104

Showing results (911-920 of 1,035) with videos related to

Sort By:
Pageof 104
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian CancerStephanie L Wethington, Payal D Shah, Lainie Martin, et al.
International Journal of Cancer|April 23, 2016
Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanomaNicholas J Taylor, Nancy E Thomas, Hoda Anton-Culver, et al.
Gynecologic Oncology|February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology studyJessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based studyMarianne Berwick, Irene Orlow, Amanda J Hummer, et al.
Breast Cancer Research and Treatment|December 19, 2018
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapiesBerry Button, Sarah Croessmann, David Chu, et al.
Cancer Causes & Control : CCC|January 9, 2007
Ambient UV, personal sun exposure and risk of multiple primary melanomasAnne Kricker, Bruce K Armstrong, Chris Goumas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancerA M Hong, A Martin, B K Armstrong, et al.
The British Journal of Dermatology|September 15, 2019
A risk prediction model for the development of subsequent primary melanoma in a population-based cohortA E Cust, C Badcock, J Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2025
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline UpdateStéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, et al.
BMC Cancer|October 19, 2013
MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family studyAnne E Cust, Chris Goumas, Kylie Vuong, et al.
Pageof 104